Global Report - Pharmaceutical Executive


Global Report
News, markets, and regulation in Europe, Asia, and South America.

EMA—a Pioneer Permanently At Bay

November 1, 2014

Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.

EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire?

August 1, 2014

Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.

Europe Gears Up to Attack Counterfeit Medicines—But Only Some of Them

July 1, 2014

Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.

Hopes High as EU Heads Into Leadership Change

June 1, 2014

Rare allies—innovator and generic pharmas—are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.

Whatever Happened To Faster Reimbursement For Generics In Europe?

April 1, 2014

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.

The Italian's Job

March 1, 2012

After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director—with great challenges ahead.

Industry/Gov't R&D Support: So Far So Good

February 1, 2012

The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.

Here's to a Happier New Year?

January 1, 2012

A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.

Europe's Transparency Directive Revisited

December 1, 2011

The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?


Click here